RayzeBio is a biotechnology company that aims to improve clinical benefit by efficiently developing innovative tumor-targeted small molecule medicines that harness the power of radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel macrocyclic peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020 by co-founders Deborah Charych, Aaron Kantoff, and Aron Knickerbocker.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/14/20 | $45,000,000 | Series A |
Samsara BioCapital VenBio  Versant Ventures | undisclosed |
